SCHEMBL6713912

SCHEMBL6713912

CC(=O)Sc1ccccc1C(C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA4 P22748 1/20 0.53
▸ CA7 P43166 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ MMP2 P08253 2/20 0.42
▸ MMP9 P14780 2/20 0.42
▸ MMP8 P22894 2/20 0.42
▸ MMP12 P39900 2/20 0.42
▸ MMP13 P45452 2/20 0.42
▸ MMP14 P50281 2/20 0.42
▸ MMP16 P51512 2/20 0.42
▸ CXCL8 P10145 2/20 0.42
▸ MMP1 P03956 1/20 0.42
▸ PTGS2 P35354 7/20 0.42
▸ PTGS1 P23219 5/20 0.41
▸ MMP3 P08254 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CXCR1 P25024 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723569 1.00 CA12 (0.53) CA12CA1CA2CA4CA7
SCHEMBL27288084 0.84 PTGS1 (0.43) CA12CA1CA2CA4CA7
SCHEMBL10585500 0.83 CA1 (0.53) CA12CA1CA2CA4CA7
SCHEMBL2209026 0.81 PTGS2 (0.44) MMP2MMP9MMP8MMP12MMP13
SCHEMBL18797642 0.81 PTGS2 (0.50) MMP2MMP9MMP8MMP12MMP13
SCHEMBL18113105 0.79 PTGS1 (0.41) MMP2MMP9MMP8MMP12MMP13
SCHEMBL9235115 0.79 SIRT1 (0.47) MMP2MMP9MMP8MMP12MMP13
SCHEMBL2204495 0.78 PTGS2 (0.56) MMP2MMP9MMP8MMP12MMP13
SCHEMBL16556233 0.77 MMP2 (0.41) MMP2MMP9MMP8MMP12MMP13
SCHEMBL14097981 0.75 MMP2 (0.39) MMP2MMP9MMP8MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040069208-A1 Process for crystallizing enantiomerically enriched 2-acetylthio-3-phenylpropionic acid DSM IP ASSETS B.V. (NL) 2004-04-15 — — US claimed
EP-1313702-A1 PROCESS FOR CRYSTALLIZING ENANTIOMERICALLY ENRICHED 2-ACETYLTHIO-3-PHENYLPROPIONIC ACID DSM N.V. (NL) 2003-05-28 — — EP claimed
WO-2002006217-A1 PROCESS FOR CRYSTALLIZING ENANTIOMERICALLY ENRICHED 2-ACETYLTHIO-3-PHENYLPROPIONIC ACID DSM N.V. (NL) 2002-01-24 — — WO claimed
US-20040069208-A1 Process for crystallizing enantiomerically enriched 2-acetylthio-3-phenylpropionic acid DSM IP ASSETS B.V. (NL) 2004-04-15 — — US disclosed
US-20040069208-A1 Process for crystallizing enantiomerically enriched 2-acetylthio-3-phenylpropionic acid DSM IP ASSETS B.V. (NL) 2004-04-15 — — US disclosed
EP-1313702-A1 PROCESS FOR CRYSTALLIZING ENANTIOMERICALLY ENRICHED 2-ACETYLTHIO-3-PHENYLPROPIONIC ACID DSM N.V. (NL) 2003-05-28 — — EP disclosed
EP-1313702-A1 PROCESS FOR CRYSTALLIZING ENANTIOMERICALLY ENRICHED 2-ACETYLTHIO-3-PHENYLPROPIONIC ACID DSM N.V. (NL) 2003-05-28 — — EP disclosed
WO-2002006217-A1 PROCESS FOR CRYSTALLIZING ENANTIOMERICALLY ENRICHED 2-ACETYLTHIO-3-PHENYLPROPIONIC ACID DSM N.V. (NL) 2002-01-24 — — WO disclosed
WO-2002006217-A1 PROCESS FOR CRYSTALLIZING ENANTIOMERICALLY ENRICHED 2-ACETYLTHIO-3-PHENYLPROPIONIC ACID DSM N.V. (NL) 2002-01-24 — — WO disclosed
CN-1046525-C Compounds containing a fused bicyclic ring and processes therefor BRISTOL MYERS SQUIBB CO (US) 1999-11-17 — — CN disclosed
CN-1039008-C Dual action inhibitors SQUIBB & SONS INC (US) 1998-07-08 — — CN disclosed
CN-1099392-A Compounds containing a fused bicyclic ring and processes therefor BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 — — CN disclosed
CN-1084849-A Dual action inhibitors SQUIBB & SONS INC (US) 1994-04-06 — — CN disclosed
Send feedback